
<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>Push enteroscopy and colonoscopy in melena patients with negative esophagogastroduodenoscopy: Prospective multicenter study</title>
<style>

<style>
body {
    font-family: 'Segoe UI', Tahoma, Geneva, Verdana, sans-serif;
    background: linear-gradient(135deg, #f0f4ff, #fafafa);
    color: #2c2c2c;
    padding: 40px;
}

/* Mindmap container */
.mindmap {
    max-width: 900px;
    margin: auto;
    font-size: 16px;
    line-height: 1.7;
}

.mindmap ul {
    margin: 0.5em 0 1em 1em;
    padding-left: 1.5em;
    list-style: disc;
    color: #555;
    font-size: 0.95em;
    font-weight: 400;
    line-height: 1.6;
}

.mindmap li::marker {
    color: #a855f7; /* prettier bullets */
}

.mindmap li {
    margin-bottom: 6px;
    padding-left: 4px;
}


/* Collapsible sections */
.mindmap details {
    border-left: 4px solid #8b5cf6;
    background: #ffffff;
    margin: 15px 0;
    padding: 16px 20px;
    border-radius: 16px;
    box-shadow: 0 4px 12px rgba(139, 92, 246, 0.12);
    transition: all 0.3s ease;
    position: relative;
}

/* Hover glow */
.mindmap details:hover {
    box-shadow: 0 6px 18px rgba(139, 92, 246, 0.2);
    background: linear-gradient(135deg, #ffffff, #f3f0ff);
}

/* Summary styling */
.mindmap summary {
    cursor: pointer;
    font-size: 1.15em;
    font-weight: 600;
    list-style: none;
    position: relative;
    padding-left: 28px;
    color: #4c1d95;
}

/* Custom arrow */
.mindmap summary::before {
    content: "▶";
    position: absolute;
    left: 0;
    top: 2px;
    transition: transform 0.3s ease;
    font-size: 1em;
    color: #7c3aed;
}

.mindmap details[open] > summary::before {
    transform: rotate(90deg);
}

/* Titles */
.mindmap summary strong {
    display: block;
    font-size: 1.3em;
    color: #4c1d95;
}

.mindmap summary em {
    font-style: normal;
    color: #6b21a8;
    font-size: 0.95em;
}

/* Description bullets */
.mindmap ul {
    padding-left: 22px;
    margin-top: 10px;
    margin-bottom: 12px;
}

.mindmap li {
    margin-bottom: 6px;
    font-size: 0.97em;
    color: #444;
    list-style-type: disc;
    position: relative;
    padding-left: 4px;
}

/* Nesting indent style */
.mindmap details > div > details {
    margin-left: 20px;
    border-color: #a855f7;
    background: #f9f5ff;
}

/* Fade-in effect */
.mindmap details[open] > div {
    animation: fadeIn 0.3s ease-in;
}

/* Description box */
.mindmap .desc-box {
    background: #fdfcff;
    border: 1px solid #e5d9fb;
    border-left: 4px solid #c084fc;
    padding: 4px 6px;
    margin: 12px 0 18px 0;
    border-radius: 12px;
    box-shadow: 0 1px 3px rgba(160, 104, 255, 0.06);
    transition: background 0.3s ease;
}

.mindmap .desc-box:hover {
    background: #f9f4ff;
}


button {
    background-color: #7c3aed;
    color: white;
    border: none;
    padding: 10px 16px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease;
}
button:hover {
    background-color: #6b21a8;
}


@keyframes fadeIn {
    from { opacity: 0; transform: translateY(-3px); }
    to { opacity: 1; transform: translateY(0); }
}


#level-controls button {
    background-color: rgba(124, 58, 237, 0.7); /* semi-transparent purple */
    color: white;
    border: none;
    padding: 8px 14px;
    margin: 0 6px;
    font-size: 1em;
    border-radius: 8px;
    cursor: pointer;
    transition: background 0.3s ease, transform 0.2s;
}

#level-controls button:hover {
    background-color: rgba(107, 33, 168, 0.85); /* slightly darker on hover */
    transform: scale(1.05);
}

#level-controls {
    position: fixed;
    bottom: 20px;
    left: 50%;
    transform: translateX(-50%);
    background: rgba(124, 58, 237, 0.1);
    padding: 8px 14px;
    border-radius: 12px;
    box-shadow: 0 4px 10px rgba(0, 0, 0, 0.1);
    z-index: 9999;
    backdrop-filter: blur(6px);
    cursor: move; /* shows move cursor */
}

</style>




</style>
</head>
<body>
<div id="level-controls" onmousedown="dragElement(this)">
    <button onclick="setMindmapLevel(1)">Level 1</button>
    <button onclick="setMindmapLevel(2)">Level 2</button>
    <button onclick="setMindmapLevel(3)">Level 3</button>
</div>

<div class="mindmap">

    <div class="mindmap">
        
        <details>
            <summary><strong>Push enteroscopy and colonoscopy in melena patients with negative esophagogastroduodenoscopy: Prospective multicenter study</strong></summary>
            <div>
                <ul><li>Info about the article:</li><li>Authors: Kotchakon Maipang, Julajak Limsrivilai, et al.</li><li>Journal: Endosc Int Open</li><li>Publication Date: 2025</li><li>DOI: 10.1055/a-2676-3957</li><li>Study Design: Prospective, multicenter cohort study</li></ul>
                
        <details>
            <summary><strong>Knowledge Test</strong></summary>
            <div>
                <ul><li>1. What percentage of patients with melena have a non-diagnostic EGD?</li><li>2. What is the reported diagnostic yield of colonoscopy in melena patients with negative EGD in this study?</li><li>3. What is the diagnostic yield of push enteroscopy in melena patients with negative EGD in this study?</li><li>4. What is the combined diagnostic yield of push enteroscopy and colonoscopy in this study?</li><li>5. What are the limitations of VCE?</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Introduction</strong></summary>
            <div>
                <ul><li>Melena often indicates upper GI bleeding.</li><li>EGD is the initial test.</li><li>EGD fails to find the source in ≈25% of patients.</li></ul>
                
        <details>
            <summary><strong>Colonoscopy Recommendations</strong></summary>
            <div>
                <ul><li>Guidelines suggest colonoscopy after negative EGD.</li><li>Based on older studies showing 23%-35% detection rates.</li><li>Recent large study found only 4.7% yield.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Small Bowel Evaluation</strong></summary>
            <div>
                <ul><li>4%-15% of overt GI bleeds remain unexplained after EGD &amp; colonoscopy.</li><li>Considered potential small bowel bleeding.</li><li>VCE is recommended due to high yield &amp; non-invasiveness.</li></ul>
                
        <details>
            <summary><strong>VCE Limitations</strong></summary>
            <div>
                <ul><li>Misses proximal lesions due to rapid transit.</li><li>Cannot perform therapeutic interventions.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Push Enteroscopy (PE)</strong></summary>
            <div>
                <ul><li>Valuable for obscure GI bleeding.</li><li>Straightforward technique.</li><li>Retrospective study showed 40% diagnostic yield in melena.</li></ul>
                
        <details>
            <summary><strong>PE Benefits</strong></summary>
            <div>
                <ul><li>May avoid unnecessary colonoscopy &amp; VCE.</li><li>Potentially reduces treatment costs.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Study Aim</strong></summary>
            <div>
                <ul><li>Evaluate diagnostic yields of PE &amp; colonoscopy in melena patients w/ negative EGD.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Patients and Methods</strong></summary>
            <div>
                <ul><li>Prospective, multicenter cohort study.</li><li>July 2019 – October 2022.</li><li>Four referral centers in Thailand.</li></ul>
                
        <details>
            <summary><strong>Patient Selection</strong></summary>
            <div>
                <ul><li>Inclusion: Melena (black, tarry stools), age ≥18, negative EGD.</li><li>Exclusion: Unstable hemodynamics (BP &lt;90/60 mmHg despite inotropes), respiratory compromise, uncorrectable bleeding disorders, pregnancy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Data Collection</strong></summary>
            <div>
                <ul><li>Demographics, comorbidities, bleeding characteristics.</li><li>PE followed by colonoscopy.</li><li>Time to each procedure &amp; findings documented.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Culprit Lesions</strong></summary>
            <div>
                <ul><li>Ulcers, angiodysplasia, Dieulafoy’s lesions, tumors, diverticula, other abnormalities.</li><li>Colonoscopy not done if PE found culprit lesion &amp; high risk of colonoscopy complications.</li><li>Colonoscopy presumed negative in these cases.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Follow-up</strong></summary>
            <div>
                <ul><li>3-month follow-up w/o rebleeding to confirm absence of additional bleeding sources after PE.</li><li>Further investigations at physician&#x27;s discretion if both PE &amp; colonoscopy negative.</li><li>Diagnostic &amp; therapeutic yields compared.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PE Procedure</strong></summary>
            <div>
                <ul><li>PCF-Q180AL or PCF-HQ190 L/I pediatric colonoscopes.</li><li>6-8 hour fast.</li><li>IV propofol sedation.</li><li>Hyoscine butyl-bromide for motility reduction if needed.</li></ul>
                
        <details>
            <summary><strong>PE Technique</strong></summary>
            <div>
                <ul><li>Oral insertion, advanced to proximal small intestine.</li><li>Minimal insufflation (air).</li><li>Careful inspection during withdrawal.</li><li>Monitored recovery.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Statistical Analysis</strong></summary>
            <div>
                <ul><li>Descriptive statistics.</li><li>T-test or Wilcoxon rank-sum test for continuous data.</li><li>Chi-square or Fisher exact test for categorical data.</li><li>McNemar test for diagnostic yield differences.</li></ul>
                
        <details>
            <summary><strong>Significance</strong></summary>
            <div>
                <ul><li>P &lt; 0.05 considered statistically significant.</li><li>SAS OnDemand for Academics.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Ethical Considerations</strong></summary>
            <div>
                <ul><li>Written informed consent.</li><li>Approved by local IRB (Si-484/2019).</li><li>Good clinical practices.</li><li>Registered w/ ClinicalTrials.gov (NCT06574542).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Results</strong></summary>
            <div>
                <ul><li>221 patients w/ melena &amp; no hematemesis underwent EGD.</li><li>EGD identified bleeding sources in 141 (63.8%).</li><li>3 excluded due to respiratory compromise.</li></ul>
                
        <details>
            <summary><strong>Study Population</strong></summary>
            <div>
                <ul><li>77 patients (34.8%) w/ nondiagnostic EGD included.</li><li>Mean age: 67.8 years.</li><li>51.9% men.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Comorbidities</strong></summary>
            <div>
                <ul><li>Hypertension (64.9%).</li><li>Diabetes mellitus (33.8%).</li><li>Chronic kidney disease (33.8%).</li><li>Atrial fibrillation/valvular heart disease (26.0%).</li><li>Coronary artery disease (19.5%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Medications</strong></summary>
            <div>
                <ul><li>NSAID use (9.1%).</li><li>Antiplatelet use (27.3%).</li><li>Anticoagulant use (24.7%).</li><li>Warfarin overdose (6.5%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Previous Bleeding</strong></summary>
            <div>
                <ul><li>24.7% had a history of previous bleeding.</li><li>No patients w/ surgically altered upper GI anatomy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Endoscopic Procedures Timing</strong></summary>
            <div>
                <ul><li>All 77 patients underwent PE, 59 underwent colonoscopy.</li><li>Median time from presentation to EGD: 3 days (IQR 1-5).</li><li>Median time to PE: 3 days (IQR 2-6).</li><li>Median time to colonoscopy: 5 days (IQR 3-7).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Procedure Duration &amp; Complications</strong></summary>
            <div>
                <ul><li>Mean PE time: 27.9 ± 13.9 minutes.</li><li>Mean colonoscopy time: 31.4 ± 28.7 minutes.</li><li>No serious complications (bleeding/perforation).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Diagnostic Yield</strong></summary>
            <div>
                <ul><li>PE: 27/77 (35.0%) had culprit lesion identified.</li><li>Colonoscopy: 10/59 (12.9%) had bleeding source identified.</li><li>PE yield significantly greater than colonoscopy (P = 0.005).</li></ul>
                
        <details>
            <summary><strong>PE Lesion Types</strong></summary>
            <div>
                <ul><li>Ulcers (25.9%).</li><li>Angiodysplasia (29.6%).</li><li>Dieulafoy’s lesion (11.1%).</li><li>Tumor (14.8%).</li><li>Polyps (3.7%).</li><li>Bleeding diverticulum (3.7%).</li><li>Other (11.1%).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PE Lesion Locations</strong></summary>
            <div>
                <ul><li>Duodenum reached by EGD: 5 patients.</li><li>Duodenum not reached by EGD: 2 patients.</li><li>Jejunum: 22 patients.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Lesions Missed by EGD</strong></summary>
            <div>
                <ul><li>5 patients (18.5%) had lesions missed during EGD.</li><li>Duodenal ulcers, duodenal angiodysplasia, hemosuccus pancreaticus.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Colonoscopy Lesion Types</strong></summary>
            <div>
                <ul><li>Ulcers (3 patients).</li><li>Dieulafoy’s lesions (3 patients).</li><li>Cancer (1 patient).</li><li>Polyp (1 patient).</li><li>Diverticulum (1 patient).</li><li>Colitis (1 patient).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Combined Diagnostic Yield</strong></summary>
            <div>
                <ul><li>PE + Colonoscopy: 48% (37 patients).</li><li>Significantly greater than PE alone (P = 0.002) or colonoscopy alone (P &lt; 0.0001).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Predictive Factors</strong></summary>
            <div>
                <ul><li>Univariate analysis: No significant associations between age, sex, comorbidities, medications, BUN/Cr ratio &amp; positive PE findings.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Therapeutic Interventions</strong></summary>
            <div>
                <ul><li>PE: 13 patients (16.9%), successful in 12 (15.6%).</li><li>Colonoscopy: 5 patients (6.5%), successful in all 5 (6.5%).</li><li>Combined PE &amp; colonoscopy significantly ↑ successful therapeutic intervention rate.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Rebleeding Rate</strong></summary>
            <div>
                <ul><li>30-day rebleeding rate: 3.7% for PE, 0% for colonoscopy.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Further Investigations</strong></summary>
            <div>
                <ul><li>VCE (10 patients).</li><li>CT (6 patients).</li><li>BAE (4 patients).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Definitive Diagnosis</strong></summary>
            <div>
                <ul><li>Definitive source identified in 53 patients (68.8%) via initial procedures &amp; further investigations.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Discussion</strong></summary>
            <div>
                <ul><li>Melena implies upper GI bleeding → EGD first-line.</li><li>Study supports this: 64% of patients had bleeding sources found via EGD.</li><li>Previous study: ≈75% had lesions detected on EGD.</li></ul>
                
        <details>
            <summary><strong>Colonoscopy After Negative EGD</strong></summary>
            <div>
                <ul><li>Guidelines recommend colonoscopy before small bowel evaluation.</li><li>This study: diagnostic yield of 14%, lower than previous retrospective reports (23%-35%).</li><li>5%-10% of lesions detected were colon cancers.</li></ul>
                
        <details>
            <summary><strong>Colonoscopy Benefits</strong></summary>
            <div>
                <ul><li>Cancer detection.</li><li>Therapeutic interventions (successful in 5/10 lesions).</li><li>Accessibility.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>VCE</strong></summary>
            <div>
                <ul><li>Recommended after negative EGD &amp; colonoscopy (potential small bowel bleeding).</li><li>High diagnostic yield (55%-65%) for overall potential small bowel bleeding.</li><li>Limited data for melena specifically.</li></ul>
                
        <details>
            <summary><strong>VCE Limitations</strong></summary>
            <div>
                <ul><li>Misses proximal lesions (major papilla visualized in only 10.4%-43.6%).</li><li>Cannot perform therapeutic interventions.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>VCE in Melena</strong></summary>
            <div>
                <ul><li>Mussetto et al.: VCE yield in melena &amp; negative EGD = 83.3% (10/12 patients).</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Early Direct Enteroscopy</strong></summary>
            <div>
                <ul><li>Could be beneficial for vascular lesions (Dieulafoy&#x27;s, angiodysplasia) that may not be actively bleeding during VCE.</li><li>Small bowel angiodysplasia often in proximal small bowel (67% in duodenum/ligament of Treitz).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Push Enteroscopy Role</strong></summary>
            <div>
                <ul><li>Substantial possibility of proximal small bowel bleeding in melena.</li><li>Limited evidence on PE in melena.</li><li>Previous trials included melena/hematochezia: diagnostic yield 19%-35%.</li></ul>
                
        <details>
            <summary><strong>Lepère et al. Study</strong></summary>
            <div>
                <ul><li>Retrospective study.</li><li>Overall PE yield = 34%.</li><li>Melena: 40%.</li><li>Hematochezia: 17%.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Current Study Findings</strong></summary>
            <div>
                <ul><li>First prospective analysis of PE in melena w/ negative EGD.</li><li>Diagnostic yield = 35%.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>PE Benefits</strong></summary>
            <div>
                <ul><li>Therapeutic interventions (13/27 patients, 12 successful).</li><li>Safe (no serious complications).</li><li>Simple technique, most endoscopists can perform.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>ACG Guidelines</strong></summary>
            <div>
                <ul><li>Recommend PE as option in GI bleeding w/ negative EGD &amp; colonoscopy before VCE.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PE Advantage</strong></summary>
            <div>
                <ul><li>May reduce need for bowel preparation (required for colonoscopy).</li><li>Relevant for hospitalized patients (bowel prep often suboptimal).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>PE Drawback</strong></summary>
            <div>
                <ul><li>Limited reach (≈0.6 meters distal to duodenojejunal junction).</li><li>Melena can originate from more distal bleeding.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Predictors for Proximal Bleeding</strong></summary>
            <div>
                <ul><li>Lepère et al.: Chronic renal failure associated w/ positive PE findings.</li><li>Current study: No significant predictive factors identified (age, sex, comorbidities, medications, BUN/Cr ratio).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>BAE</strong></summary>
            <div>
                <ul><li>High diagnostic yield (comparable to VCE) in potential small bowel bleeding.</li><li>Deeper insertion → greater diagnostic yield.</li><li>Can perform therapeutic interventions.</li></ul>
                
        <details>
            <summary><strong>BAE Limitations</strong></summary>
            <div>
                <ul><li>Complications: sedation-related, bleeding, perforation, pancreatitis.</li><li>Unavailable at many centers, requires skilled endoscopists.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Proposed Approach</strong></summary>
            <div>
                <ul><li>PE should be performed in melena w/ negative EGD.</li><li>Consider before colonoscopy.</li><li>PE &amp; colonoscopy complement each other.</li></ul>
                
        <details>
            <summary><strong>Combined Approach</strong></summary>
            <div>
                <ul><li>PE + Colonoscopy: ↑ diagnostic yield to 48%.</li><li>↑ therapeutic intervention rates.</li><li>If PE negative → colonoscopy.</li><li>After negative PE &amp; colonoscopy → VCE, consider BAE based on VCE findings.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Study Strengths</strong></summary>
            <div>
                <ul><li>First prospective investigation of consecutive melena patients w/ negative EGD.</li><li>Assessed diagnostic &amp; therapeutic yields of PE &amp; colonoscopy.</li><li>Timely treatment (interventions in same/nearly same session).</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Study Limitations</strong></summary>
            <div>
                <ul><li>Colonoscopy not performed in every patient due to safety concerns.</li><li>May have missed additional lesions.</li><li>Addressed w/ 3-month follow-up for recurrent bleeding.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Referral Bias</strong></summary>
            <div>
                <ul><li>Significant proportion from large tertiary referral centers.</li><li>May not reflect typical case mix in general/community hospitals.</li><li>Diagnostic yields may not be fully generalizable.</li></ul>
                
            </div>
        </details>
        
        <details>
            <summary><strong>Adjunctive Tool</strong></summary>
            <div>
                <ul><li>PE may serve as valuable adjunctive tool, enhancing diagnostic &amp; therapeutic outcomes, especially where available.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
        <details>
            <summary><strong>Conclusions</strong></summary>
            <div>
                <ul><li>EGD is essential in evaluating melena patients.</li><li>If EGD negative, consider PE before/with colonoscopy.</li><li>Future studies w/ larger sample sizes needed.</li></ul>
                
            </div>
        </details>
        
            </div>
        </details>
        
    </div>
    
</div>


<script>
function setMindmapLevel(level) {
    const allDetails = document.querySelectorAll('.mindmap details');

    // Close all
    allDetails.forEach(detail => detail.removeAttribute('open'));

    // Open based on depth
    allDetails.forEach(detail => {
        let depth = 0;
        let parent = detail.parentElement;
        while (parent && parent.tagName !== 'BODY') {
            if (parent.tagName === 'DETAILS') depth++;
            parent = parent.parentElement;
        }
        if (depth < level) detail.setAttribute('open', '');
    });
}

// Automatically open to level 1 on page load
window.addEventListener('DOMContentLoaded', () => {
    setMindmapLevel(1);
});

function dragElement(elmnt) {
    let pos1 = 0, pos2 = 0, pos3 = 0, pos4 = 0;

    const onMouseDown = (e) => {
        e.preventDefault();
        pos3 = e.clientX;
        pos4 = e.clientY;
        document.onmouseup = closeDragElement;
        document.onmousemove = elementDrag;
    };

    const elementDrag = (e) => {
        e.preventDefault();
        pos1 = pos3 - e.clientX;
        pos2 = pos4 - e.clientY;
        pos3 = e.clientX;
        pos4 = e.clientY;
        elmnt.style.top = (elmnt.offsetTop - pos2) + "px";
        elmnt.style.left = (elmnt.offsetLeft - pos1) + "px";
        elmnt.style.transform = "none"; // cancel centering transform
        elmnt.style.bottom = "auto"; // cancel fixed bottom
    };

    const closeDragElement = () => {
        document.onmouseup = null;
        document.onmousemove = null;
    };

    onMouseDown(event);
}
</script>


</body>
</html>
